Milestone Pharmaceuticals (MIST)
(Delayed Data from NSDQ)
$1.33 USD
+0.01 (0.38%)
Updated Jul 5, 2024 04:00 PM ET
After-Market: $1.35 +0.02 (1.50%) 7:58 PM ET
3-Hold of 5 3
F Value D Growth F Momentum F VGM
Milestone Pharmaceuticals (MIST) Price Targets
Average Price Target | Highest Price Target | Lowest Price Target | Upside to Average Price Target |
---|---|---|---|
$10.25 | $25.00 | $2.00 | 659.26% |
Price Target
Based on short-term price targets offered by four analysts, the average price target for Milestone Pharmaceuticals comes to $10.25. The forecasts range from a low of $2.00 to a high of $25.00. The average price target represents an increase of 659.26% from the last closing price of $1.35.
Analyst Price Targets (4 )
Broker Rating
Milestone Pharmaceuticals currently has an average brokerage recommendation (ABR) of 1.50 on a scale of 1 to 5 (Strong Buy to Strong Sell), calculated based on the actual recommendations (Buy, Hold, Sell etc.) made by four brokerage firms. The current ABR compares to an ABR of 1.50 a month ago based on four recommendations.
Of the four recommendations deriving the current ABR, three are Strong Buy, representing 75% of all recommendations. A month ago, Strong Buy represented 75%.
Broker Rating Breakdown
Brokerage Recommendations
Today | 1 Week Ago | 1 Month Ago | 2 Months Ago | 3 Months Ago | |
---|---|---|---|---|---|
Strong Buy | 3 | 3 | 3 | 3 | 3 |
Buy | 0 | 0 | 0 | 0 | 0 |
Hold | 1 | 1 | 1 | 1 | 1 |
Sell | 0 | 0 | 0 | 0 | 0 |
Strong Sell | 0 | 0 | 0 | 0 | 0 |
ABR | 1.50 | 1.50 | 1.50 | 1.50 | 1.50 |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Analyst Upgrades/Downgrades
Date | Brokerage Firm | Analyst | Previous | Current |
---|---|---|---|---|
7/1/2024 | H.C. Wainwright & Co. | Patrick Trucchio | Strong Buy | Strong Buy |
6/20/2024 | Piper Sandler | Edward A Tenthoff | Strong Buy | Strong Buy |
4/1/2024 | Cowen & Co. | Ritu S Baral | Strong Buy | Strong Buy |
1. Not Ident. Many of the brokerage firms who provide Zacks data ask that we keep their identity confidential.
2. In most cases the # of brokers listed above is less than the # of brokerage firms that have a recommendation on the stock. That is because some firms prohibit Zacks from displaying detailed information on their recommendations such as in the upgrade/downgrade table.
Average Brokerage Rating
Current ABR | 1.50 |
ABR (Last week) | 1.50 |
# of Recs in ABR | 4 |
Average Target Price | $10.25 |
LT Growth Rate | NA |
Industry | Medical - Biomedical and Genetics |
Industry Rank by ABR | 84 of 252 |
Current Quarter EPS Est: | -0.19 |